Conditions: Rheumatoid Arthritis
Keywords: abatacept, methotrexate, erosive RA
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1052
Healthy volunteers: no

Brief summary:
This is a world wide study to evaluate the remission and joint damage in subjects treated with abatacept in addition to methotrexate versus subjects who receive methotrexate along with a placebo.

Detailed description:

Arms:
arm 1: abatacept 10 mg/kg intravenous (IV) + methotrexate arm 2: placebo IV + methotrexate

Interventions: intervention 1: Abatacept intervention 2: placebo intervention 3: methotrexate
Intervention descriptions: intervention 1: abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months intervention 2: placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months intervention 3: Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24

Protocol document: